Womens Health: Worldwide Prescription Drug Markets

Questions: Discounts, Updates etc.

Pages: 408

Price (Single): $3900

Price (Departmental):

Price (Company):

Publication Date: 2006-08-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The past 25 years have seen unprecedented advancements in the area of womens health. A number of events have helped to bring the concerns of women’s health to the forefront of medicine but the most significant was the women’s health movement, which increased attention to women’s health issues and the shortcomings of traditional medical practice and research. The National Institutes of Health, the American Medical Association, and the Office of Research on Women’s Health were all instrumental in affecting changes. Large studies are now conducted to gather data on the prevention and treatment of the major causes of death in middle-aged and older women, including cancer and osteoporosis. A number of societies have been established to bring attention to serious shortcomings and unmet needs in women’s health research worldwide with the focus on the study of diseases that affect only women and the secondary influence of reproduction on other physiological systems. Thanks to insistent congresswomen, women’s health activists, pressure from advocacy groups like the National Women’s Health Network and the Public Citizen’s Health Research Group, women’s health issues have risen to the public awareness.

The market for prescription drugs to treat the constellation of conditions that make up the discipline of womens health has followed consciousness raising efforts. This report provides market size, growth, and share for the following product categories:

Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2005. Historical data are provided for each of the years 2000 through 2005, and forecast data are provided for each of the years 2006 through 2010. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2005 base year.

In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.

Table of Contents

Chapter One: Executive Summary
  • Scope and Methodology
  • Size and Growth of the Market
  • Trends Affecting the Market
  • Market Outlook

Chapter Two: Introduction and Overview

  • History of Women’s Health
  • Female Reproductive System
  • Hormone Regulation
  • Demographics
  • Epidemiology
    • Autoimmune Disease
    • Cancer
    • Gynecological Infection and Sexually Transmitted Disease
    • Hormone-Related Indications
    • Osteoporosis
    • Urinary Bladder Disorders
    • Lifestyle Patterns

Chapter Three: Autoimmune Diseases

  • Overview
  • Chronic Fatigue Syndrome
  • Treatment
  • Fibromyalgia
  • Treatment
  • Rheumatoid Arthritis
  • Treatment
  • Scleroderma
  • Treatment
  • Sjogren’s Syndrome
  • Treatment
  • Systemic Lupus Erythematosus
  • Treatment
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
    • 406381
    • Anergix RA
    • Ampligen
    • Actemra
    • Apilmod
    • Arcoxia
    • CDP 870
    • CTLA 41G
    • Denosumab
    • Interleukin (IL-1)
    • LymphoStat-B
    • MabThera
    • Milnacipran
    • Prestara
    • Prexige
    • Prograf
    • Org 39141
    • Riquent
    • Veldona
  • Competitive Market

Chapter Four: Cancer

  • Overview
  • Breast Cancer
    • Overview
    • Treatment
  • Cervical Cancer
    • Overview
    • Treatment
  • Endometrial Cancer
    • Overview
    • Treatment
  • Ovarian Cancer
    • Overview
    • Treatment
  • Vaginal Cancer
    • Overview
    • Treatment
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
    • Advexin
    • Arzoxifene
    • Atamestane
    • Avastin
    • BrevaRex
    • Cervarix
    • Combidex
    • Edotecarin
    • Evista
    • Herceptin
    • Ixabepilone
    • Lapatinib
    • Lasofoxifene
    • MDX-010
    • Myocet
    • OvaRex
    • Pemtumomab
    • Tavocept
    • Taxoprexin
    • Telcyta
    • Temsirolimus
    • Tykerb
    • Vinorelbine IV
    • Xinlay
    • XRP 98
    • Xytotax
    • Yondelis
  • Competitive Market

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

  • Overview
  • AIDS
    • Overview
    • Treatment
    • Agenerase
    • Aptivus
    • Combivir
    • Crixivan
    • Entriva
    • Fortovase
    • Fuzeon
    • Hivid
    • Invirase
    • Kaletra
    • Kivexa
    • Lexiva
    • Prezista
    • Rescriptor
    • Reyataz
    • Sustiva
    • Trizivir
    • Truvada
    • Viracept
    • Viramune
  • Bacterial Vaginosis
    • Overview
    • Treatment
  • Cervical Dysplasia
    • Overview
    • Treatment
  • Chlamydia
    • Overview
    • Treatment
  • Condyloma Acuminata
    • Overview
    • Treatment
    • Aldara
    • Alferon N Injection
    • Condylox
    • Gardasil
  • Genital Herpes
    • Overview
    • Treatment
    • Zovirax
  • Gonorrhea
    • Overview
    • Treatment
  • Hepatitis
    • Overview
    • Treatment
    • Baraclude
  • Pelvic Inflammatory Disease
    • Overview
    • Treatment
  • Syphilis
    • Overview
    • Treatment
  • Toxic Shock Syndrome
    • Overview
    • Treatment
  • Yeast Infections
    • Overview
  • Treatment
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
    • Ampligen
    • Aplaviroc
    • BufferGel
    • Carraguard
    • Clevudine
    • HepeX-B
    • Hyphanox
    • IFN-alpha Lozenge
    • Interferon Alfacon/Ribaviron Combination
    • Maraviroc
    • Multiferon
    • PRO 2000
    • Proleukin
    • Resiquimod
    • SAVVY
    • Simplirix
    • SPO1A
    • Telbivudine
    • Ushercell
    • Zadaxin
    • Competitive Market

Chapter Six: Hormone-Related Disorders

  • Overview
  • Contraception
    • Overview
    • Treatment
    • Oral Contraceptives
    • Depo-Provera
    • Birth Control Patch
    • Vaginal Ring
    • Emergency Contraception and Early Option
    • Implant
    • Intrauterine Device (IUD)
  • Endometriosis
    • Overview
    • Treatment
  • Fibroids
    • Overview
    • Treatment
  • Infertility
    • Overview
    • Treatment
  • Menopause
    • Overview
    • Treatment
  • Menstrual Disorders
    • Amenorrhea
    • Dysmenorrhea
  • Sexual Dysfunction
    • Overview
    • Treatment
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
    • Alista
    • Alprox-TD
    • Asoprisnil
    • Bijuva
    • Bio-E-Gel
    • BufferGel
    • E2/DNG Pill
    • Evamist
    • FC Patch
    • Femprox Cream
    • Intrinsa
    • LibiGel
    • IoGen
    • Lybrel
    • Menopausal Levonorgestrel System
    • NOMAC/E2
    • Preven Emergency Contraceptive Kit
    • Tanaproget
    • Tostrelle
  • Competitive Market

Chapter Seven: Osteoporosis

  • Overview
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
    • Aclasta
    • AMG 162
    • ALX 1-11
    • Arzoxifene
    • Banzedoxifene
    • Denosumab
    • Lasofoxifene (Oporia)
    • Livial
    • Oral Calcitonin
    • Ostarine
    • Preos
    • S12911
  • Competitive Market

Chapter Eight: Urinary Bladder Disorders

  • Overview
  • Cystitis
    • Overview
    • Treatment
  • Incontinence
    • Overview
    • Treatment
    • Overactive Bladder
    • Treatment
    • Alternative Treatments
  • Interstitial Cystitis
    • Overview
    • Treatment
  • Market Size and Growth
  • Geographical Market Analysis
  • Research and Development
  • Competitive Market

Chapter Nine: Issues and Trends

  • Women’s Health Initiative
  • Perimenopausal Use of Contraceptives
  • Fosamax Patents Void in European Market
  • Insurance Coverage for Contraceptives
  • Oral Contraceptives in Japan
  • Ovarian Cancer Test
  • New Pap Test Screening Guidelines
  • Estrogen Labeling
  • Osteoporosis Drug Opportunities in Asia
  • OTC Plan B
  • Cervical Cancer Vaccines
  • Women’s Access to Health Care and Insurance
  • Issues of Middle-Aged and Older Women
  • Possible AIDS Vaccine

Chapter Ten: World Market Summary

  • Overview
  • Total Market Size and Forecast
  • Market Analysis

Chapter Eleven: Competitor Profiles

  • Industry Structure and Participants
  • Akzo Nobel nv Organon International
  • Amgen, Inc.
  • AstraZeneca PLC
  • Barr Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Company, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Procter & Gamble Company
  • Roche
  • Sanofi -Aventis
  • Schering AG
  • Serono International S.A.
  • Wyeth

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: Market Summary: The Worldwide Market for Prescription Drugs for Women’s Healthcare 2000-2010
  • Figure 1-1: The Market for Women’s Healthcare Trending in Revenues by Segment 2000-2010

Chapter Two: Introduction and Overview

  • Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2005
  • Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2005 (Difference, in Years, between Females and Males)
  • Table 2-2: World Population Growth: Total World Population and Selected Country or Regions by Sex, 2000-2025
  • Figure 2-2: World Population Growth by Sex 2000-2025
  • Figure 2-3: United States Population Growth by Sex 2000-2025
  • Figure 2-4: Five Major European Countries* Population Growth by Sex 2000-2025
  • Figure 2-5: Japan Population Growth by Sex 2000-2025
  • Table 2-3: World Female Population Growth by Selected Country/Region and Age Group, 2000-2025
  • Figure 2-6: World Female Population Growth by Selected Age Group 2000-2025
  • Figure 2-7: United States Female Population Growth by Selected Age Group 2000-2025
  • Figure 2-8: Five Major European Countries* Female Population Growth by Selected Age Group 2000-2025
  • Figure 2-9: Japan Female Population Growth by Selected Age Group 2000-2025
  • Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type (Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis, Scleroderma, Sjogren’s Disease, Systemic Lupus Erythematosus) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
  • Table 2-5: Estimated Incidence and Mortality of Female Cancers by Type (Breast, Cervical, Endometrial, Ovarian) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
  • Table 2-6: Estimated Female Incidence/Prevalence of Gynecological and Sexually Transmitted Diseases by Type ((AIDS/HIV, Bacterial Vaginosis, Cervical Dysplasia, Chlamydia, Genital Herpes, Gonorrhea, Human Papilloma Virus, Hepatitis [Sexually Transmitted], Pelvic Inflammatory Disease, Syphilis, Toxic Shock Syndrome, Yeast Infection) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
  • Table 2-7: Gynecological and Sexually Transmitted Diseases Diagnostic Testing Procedure Volume by Type (Pap, Pelvic Exams, HIV Tests, Other STD Tests, Mammograms), Five-Year Average 2000-2005
  • Table 2-8: Estimated World and U.S. Female Incidence/Prevalence of Hormone-Related Indications by Type (Contraception, Endometriosis, Fibroids, Infertility, Menopause), Five-Year Average 2000-2005
  • Table 2-9: Estimated World and U.S. Contraceptive Use by Method ((Female Sterilization, Oral Pill, Implant, Injectable, IUD, Diaphragm, Female Condom, Other Methods), Five-Year Average 2000-2005
  • Table 2-10: Estimated Female Prevalence of Osteoporosis by Type (Diagnosed, Low-Bone Mass [At Risk], Osteoporosis-related Fractures) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
  • Table 2-11: Estimated Female Incidence/Prevalence of Urinary Bladder Disorders by Type (UTI, Incontinence, Overactive Bladder, Interstitial Cystititis) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
  • Table 2-12: Estimated Female Statistics Concerning Lifestyle Patterns Contributing to Disease by Type of Behavior and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005

Chapter Three: Autoimmune Diseases

  • Table 3-1: The World Market for Autoimmune Disease Drugs for Women by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2000-2010
  • Figure 3-1: The World Market for Autoimmune Disease Drugs for Women Revenues by Type 2000-2010
  • Figure 3-2: The World Market for Autoimmune Disease Drugs for Women Share by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2005 & 2010
  • Table 3-2: The World Market for Autoimmune Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 3-3: The World Market for Autoimmune Disease Drugs for Women Share by Geographic Region 2005 and 2010
  • Table 3-4: The World Market for Autoimmune Disease Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 3-4: The World Market for Autoimmune Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Four: Cancer

  • Table 4-1: The World Market for Cancer Drugs for Women by Type (Anti-metabolites, Alkylating Agents, Hormone Therapy, Biologic Therapies) 2000-2010
  • Figure 4-1: The World Market for Cancer Drugs for Women Revenues by Type 2000-2010
  • Figure 4-2: The World Market for Cancer Drugs for Women Share by Type 2005 and 2010
  • Table 4-2: The World Market for Cancer Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 4-3: The World Market for Cancer Drugs for Women Share Percentage 2005 and 2010
  • Table 4-3: Products in Development for Women’s Cancers (Product, Indication, Developer, Phase) 2005
  • Table 4-4: The World Market for Cancer Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2005

Chapter Five: Gynecological Infections and Sexually Transmitted Diseases

  • Table 5-1: Currently Available HIV Pharmaceuticals
  • Table 5-2: Currently Marketed Bacterial Vaginosis Pharmaceuticals
  • Table 5-3: Currently Marketed Chlamydia Pharmaceuticals
  • Table 5-4: Currently Marketed Condyloma Treatments
  • Table 5-5: Currently Marketed Herpes Virus Treatments
  • Table 5-6: Currently Marketed Hepatitis Treatments
  • Table 5-7: Currently Marketed PID Treatments
  • Table 5-8: Currently Marketed Prescription Yeast Infection Treatments
  • Table 5-9: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women by Type (Antibacterials, Antifungals, Antivirals) 2000-2010
  • Figure 5-1: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Type 2000-2010
  • Figure 5-2: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Type 2005 and 2010
  • Table 5-10: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 5-3: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Share by Geographic Region 2005 and 2010
  • Table 5-11: Products in Development for Women’s Gynecological Infections and Sexually Transmitted Diseases (Product, Indication, Developer, Phase)
  • Table 5-12: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 5-4: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Market Share by Leading Supplier 2005

Chapter Six: Hormone-Related Disorders

  • Table 6-1: Selected Oral Contraceptives Available 2005
  • Table 6-2: Selected Hormone Replacement Therapies
  • Table 6-3: The World Market for Hormone-Related Disorder Drugs for Women by Type (Contraceptives, Infertility Agents, Hormone Replacents, Other Hormone Therapies) 2000-2010
  • Figure 6-1: The World Market for Hormone-Related Disorder Drugs for Women by Type 2000-2010
  • Figure 6-2: The World Market for Hormone-related Disorder Drugs for Women Share by Type 2005 and 2010
  • Table 6-4: The World Market for Hormone-Related Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 6-3: The World Market for Hormone-Related Disorder Drugs for Women Share by Geographic Region 2005 and 2010
  • Table 6-5: Hormonal Preparations in Research and Development for Women (Product, Indication, Developer, Phase)
  • Table 6-6: The World Market for Hormone-Related Disorder Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 6-4: The World Market for Hormone-Related Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Seven: Osteoporosis

  • Table 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type (Bone Metabolism Regulators, Hormones/SERMs) 2000-2010
  • Figure 7-1: The World Market for Osteoporosis Drugs for Women Revenues by Type 2000-2010
  • Figure 7-2: The World Market for Osteoporosis Drugs for Women Share by Type 2005 and 2010
  • Table 7-2: The World Market for Osteoporosis Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2005 and 2010 Table 7-3: Products in Development for Osteoporosis (Product, Developer, Phase)
  • Table 7-4: The World Market for Osteoporosis Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 7-4: The World Market for Osteoporosis Drugs for Women Market Share by Leading Supplier 2005

Chapter Eight: Urinary Bladder Disorders

  • Table 8-1: Medications That Can Affect Urination
  • Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type (Antibiotics, Anticholinergics/Antispasmodics, Cholinergics, Other) 2000-2010
  • Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 2000-2010
  • Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2005 and 2010
  • Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
  • Figure 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Share by Geographic Region 2005 and 2010
  • Table 8-4: Products in Development for Urinary Disorders (Product, Indication, Developer, Phase)
  • Table 8-5: The World Market for Urinary Bladder Disorder Drugs for Women Revenues and Market Share by Supplier 2005
  • Figure 8-4: The World Market for Urinary Bladder Disorder Drugs for Women Market Share by Leading Supplier 2005

Chapter Ten: World Market Summary

  • Table 10-1: The Worldwide Market for Prescription Drugs in Women’s Health, Revenues by Segment (Autoimmune, Cancer, Gynecologic Infections and STDs, Hormones, Osteoporosis, Urinary Bladder Disorders), 2000-2010
  • Figure 10-1: The Market for Women’s Healthcare Revenues by Segment 2000-2010
  • Figure 10-2: The Market for Women’s Healthcare Market Share by Type 2005 and 2010
  • Table 10-2: Women’s Health Revenues and Segments of Participation by Leading Market Participants 2005

 
800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >
Most Popular Research
Anesthesia Drugs: Worldwide Markets Outsourcing in Drug Discovery: The Contract Research (CRO) Market, 3rd Edition Vaccines: The World Market Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry The Worldwide Market for Dialysis Equipment, Supplies, and Services, 2nd Edition Prescription Dermatological Drugs: Worldwide Market, 6th Edition
 

Other users found this report page using the following search terms: womens health Autoimmune diseases rheumatoid arthritis Gynecological Cancer Sexually Transmitted Diseases Hormonal disorders Osteoporosis Urinary Disorders market prescription drug share worldwide health size womens drugs 20002010

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.